NCT02468648View on ClinicalTrials.gov

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 9, 2015

Primary Completion Date

September 14, 2018

Study Completion Date

September 14, 2018

Conditions
Chronic Hepatitis C
Interventions
DRUG

Sofosbuvir

An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection

DRUG

GS-5816

An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT02468648 - Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816 | Biotech Hunter | Biotech Hunter